Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Harvard Business School
Merck
Dow
Baxter

Last Updated: August 10, 2022

GIMOTI Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Gimoti, and when can generic versions of Gimoti launch?

Gimoti is a drug marketed by Evoke Pharma Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has nine patent family members in seven countries.

The generic ingredient in GIMOTI is metoclopramide hydrochloride. There are fourteen drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the metoclopramide hydrochloride profile page.

Summary for GIMOTI
International Patents:9
US Patents:2
Applicants:1
NDAs:1
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in GIMOTI?GIMOTI excipients list
DailyMed Link:GIMOTI at DailyMed
Drug patent expirations by year for GIMOTI
Paragraph IV (Patent) Challenges for GIMOTI
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
GIMOTI Metered Nasal Spray metoclopramide hydrochloride 15 mg/spray 209388 1 2021-12-30

US Patents and Regulatory Information for GIMOTI

GIMOTI is protected by two US patents and one FDA Regulatory Exclusivity.

Patents protecting GIMOTI

Nasal formulations of metoclopramide
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: NASAL ADMINISTRATION OF METOCLOPRAMIDE FOR TREATMENT OF DIABETIC GASTROPARESIS

Nasal formulations of metoclopramide
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: NASAL ADMINISTRATION OF METOCLOPRAMIDE FOR TREATMENT OF DIABETIC GASTROPARESIS

FDA Regulatory Exclusivity protecting GIMOTI

NEW PRODUCT
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Evoke Pharma Inc GIMOTI metoclopramide hydrochloride SPRAY, METERED;NASAL 209388-001 Jun 19, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Evoke Pharma Inc GIMOTI metoclopramide hydrochloride SPRAY, METERED;NASAL 209388-001 Jun 19, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Evoke Pharma Inc GIMOTI metoclopramide hydrochloride SPRAY, METERED;NASAL 209388-001 Jun 19, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for GIMOTI

See the table below for patents covering GIMOTI around the world.

Country Patent Number Title Estimated Expiration
Canada 3155873 NASAL FORMULATIONS OF METOCLOPRAMIDE See Plans and Pricing
European Patent Office 1274414 ADMINISTRATION NASALE DE METOCLOPRAMIDE POUR TRAITER LA GASTROPARESIE (NASAL ADMINISTRATION OF METOCLOPRAMIDE FOR THE TREATMENT OF GASTROPARESIS) See Plans and Pricing
World Intellectual Property Organization (WIPO) 0174350 See Plans and Pricing
Portugal 1274414 See Plans and Pricing
Germany 60142037 See Plans and Pricing
South Korea 20030004361 See Plans and Pricing
Spain 2346290 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Express Scripts
Merck
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.